|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2004-7-5
|
|
pubmed:abstractText |
We studied a model of in vivo purging with Rituximab and high-dose (HD) cytarabine in 14 patients with relapsed/refractory follicular lymphoma and two with refractory mantle cell lymphoma enrolled in a program of HD chemotherapy and autotransplant. After two courses of debulking immunochemotherapy with Rituximab, Vincristine and Cyclophosphamide, we used a combination of Rituximab, HD cytarabine and granulocyte colony-stimulating factor for peripheral blood stem cells (PBSC) mobilization. The median number of CD34+ cells collected was 14.69 x 10(6)/kg (range 5.74-73.2). Monitoring of peripheral CD19+ and CD20+ B cells prior to and throughout the purging period showed that a treatment with Rituximab, Vincristine and Cyclophosphamide results in a profound depletion of B cells in peripheral blood. B-cell depletion persists during mobilization with Rituximab and HD cytarabine allowing a collection of PBSC free of B cells (median CD19+ and CD20+ cells counts 0%). Of nine patients PCR positive for bcl-2 or bcl-1 in blood and marrow at the start of immunochemotherapy, all showed PCR-negative PBSC. In conclusion, in patients with indolent lymphoma, the concurrent administration of Rituximab and HD cytarabine is a safe and efficient method to obtain in vivo purged PBSC. Immunochemotherapy prior to mobilization produces B-cell depletion and seems to be a useful preparative step.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
pubmed-author:AlessandrinoE PEP,
pubmed-author:ArcainiLL,
pubmed-author:BernasconiPP,
pubmed-author:BonfichiMM,
pubmed-author:BrusamolinoEE,
pubmed-author:CalatroniSS,
pubmed-author:IaconaII,
pubmed-author:LazzarinoMM,
pubmed-author:MontanaroLL,
pubmed-author:OrlandiEE,
pubmed-author:PascuttoCC,
pubmed-author:RegazziMM,
pubmed-author:TenoreAA,
pubmed-author:TrolettiDD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
175-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15170171-Adult,
pubmed-meshheading:15170171-Antibodies, Monoclonal,
pubmed-meshheading:15170171-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:15170171-Antigens, CD34,
pubmed-meshheading:15170171-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15170171-B-Lymphocytes,
pubmed-meshheading:15170171-Bone Marrow Purging,
pubmed-meshheading:15170171-Cytarabine,
pubmed-meshheading:15170171-Female,
pubmed-meshheading:15170171-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:15170171-Humans,
pubmed-meshheading:15170171-Immunophenotyping,
pubmed-meshheading:15170171-Lymphoma, Follicular,
pubmed-meshheading:15170171-Lymphoma, Mantle-Cell,
pubmed-meshheading:15170171-Male,
pubmed-meshheading:15170171-Middle Aged,
pubmed-meshheading:15170171-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:15170171-Salvage Therapy,
pubmed-meshheading:15170171-Transplantation, Autologous
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
|
|
pubmed:affiliation |
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. luca.arcaini@unipv.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
